Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D01GUK
|
||||
Former ID |
DNC012225
|
||||
Drug Name |
Cyclopentyl-(9-phenyl-9H-purin-6-yl)-amine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C16H17N5
|
||||
Canonical SMILES |
C1CCC(C1)NC2=NC=NC3=C2N=CN3C4=CC=CC=C4
|
||||
InChI |
1S/C16H17N5/c1-2-8-13(9-3-1)21-11-19-14-15(17-10-18-16(14)21)20-12-6-4-5-7-12/h1-3,8-12H,4-7H2,(H,17,18,20)
|
||||
InChIKey |
HMTXZOPPYXBLIU-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Adenosine A1 receptor | Target Info | Inhibitor | [1] | |
KEGG Pathway | cGMP-PKG signaling pathway | ||||
cAMP signaling pathway | |||||
Sphingolipid signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Morphine addiction | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
RANKL Signaling Pathway | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Reactome | Adenosine P1 receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | Nucleotide GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | J Med Chem. 1991 Sep;34(9):2877-82.N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.